Treatment options for hepatitis C infection in children

Aymin Delgado-Borrego, Maureen M. Jonas

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Multiple factors support treatment of hepatitis C virus (HCV) infection in children. These factors include the anticipated long duration of infection after early acquisition, relatively good tolerance of antiviral medications, and avoidance of social stigmatization. Nevertheless, careful selection of appropriate candidates for therapy is important. If a contraindication to current therapeutic agents is present, treatment should be withheld until this has resolved or until new agents are available. Children without contraindications to the medications used for HCV should undergo liver biopsy to determine the presence and degree of fibrosis. In the absence of fibrosis, treatment may be deferred. If any degree of hepatic fibrosis is present, antiviral therapy for HCV should be considered. At present, in the United States, the only therapy approved for children by the Food and Drug Administration (FDA) is a combination of interferon (IFN) alfa-2b and ribavirin. No safe therapies have been established for children younger than 3 years of age. Pegylated interferon in combination with ribavirin may be considered in adolescents older than 16 years of age who are post-pubertal, or in younger children in the context of clinical trials. Multicenter trials are currently underway to determine the safety and effectiveness of other forms of therapy for HCV infection in children.

Original languageEnglish
Pages (from-to)373-379
Number of pages7
JournalCurrent Treatment Options in Gastroenterology
Volume7
Issue number5
StatePublished - Oct 1 2004

Fingerprint

Hepatitis C
Infection
Hepacivirus
Fibrosis
Therapeutics
interferon alfa-2b
Ribavirin
Virus Diseases
Antiviral Agents
Stereotyping
Liver
United States Food and Drug Administration
Interferons
Multicenter Studies
Clinical Trials
Biopsy
Safety

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment options for hepatitis C infection in children. / Delgado-Borrego, Aymin; Jonas, Maureen M.

In: Current Treatment Options in Gastroenterology, Vol. 7, No. 5, 01.10.2004, p. 373-379.

Research output: Contribution to journalArticle

Delgado-Borrego, A & Jonas, MM 2004, 'Treatment options for hepatitis C infection in children', Current Treatment Options in Gastroenterology, vol. 7, no. 5, pp. 373-379.
Delgado-Borrego, Aymin ; Jonas, Maureen M. / Treatment options for hepatitis C infection in children. In: Current Treatment Options in Gastroenterology. 2004 ; Vol. 7, No. 5. pp. 373-379.
@article{bc260a49cf234347aff2e98bf2bd13d3,
title = "Treatment options for hepatitis C infection in children",
abstract = "Multiple factors support treatment of hepatitis C virus (HCV) infection in children. These factors include the anticipated long duration of infection after early acquisition, relatively good tolerance of antiviral medications, and avoidance of social stigmatization. Nevertheless, careful selection of appropriate candidates for therapy is important. If a contraindication to current therapeutic agents is present, treatment should be withheld until this has resolved or until new agents are available. Children without contraindications to the medications used for HCV should undergo liver biopsy to determine the presence and degree of fibrosis. In the absence of fibrosis, treatment may be deferred. If any degree of hepatic fibrosis is present, antiviral therapy for HCV should be considered. At present, in the United States, the only therapy approved for children by the Food and Drug Administration (FDA) is a combination of interferon (IFN) alfa-2b and ribavirin. No safe therapies have been established for children younger than 3 years of age. Pegylated interferon in combination with ribavirin may be considered in adolescents older than 16 years of age who are post-pubertal, or in younger children in the context of clinical trials. Multicenter trials are currently underway to determine the safety and effectiveness of other forms of therapy for HCV infection in children.",
author = "Aymin Delgado-Borrego and Jonas, {Maureen M.}",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "7",
pages = "373--379",
journal = "Current Treatment Options in Gastroenterology",
issn = "1092-8472",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment options for hepatitis C infection in children

AU - Delgado-Borrego, Aymin

AU - Jonas, Maureen M.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Multiple factors support treatment of hepatitis C virus (HCV) infection in children. These factors include the anticipated long duration of infection after early acquisition, relatively good tolerance of antiviral medications, and avoidance of social stigmatization. Nevertheless, careful selection of appropriate candidates for therapy is important. If a contraindication to current therapeutic agents is present, treatment should be withheld until this has resolved or until new agents are available. Children without contraindications to the medications used for HCV should undergo liver biopsy to determine the presence and degree of fibrosis. In the absence of fibrosis, treatment may be deferred. If any degree of hepatic fibrosis is present, antiviral therapy for HCV should be considered. At present, in the United States, the only therapy approved for children by the Food and Drug Administration (FDA) is a combination of interferon (IFN) alfa-2b and ribavirin. No safe therapies have been established for children younger than 3 years of age. Pegylated interferon in combination with ribavirin may be considered in adolescents older than 16 years of age who are post-pubertal, or in younger children in the context of clinical trials. Multicenter trials are currently underway to determine the safety and effectiveness of other forms of therapy for HCV infection in children.

AB - Multiple factors support treatment of hepatitis C virus (HCV) infection in children. These factors include the anticipated long duration of infection after early acquisition, relatively good tolerance of antiviral medications, and avoidance of social stigmatization. Nevertheless, careful selection of appropriate candidates for therapy is important. If a contraindication to current therapeutic agents is present, treatment should be withheld until this has resolved or until new agents are available. Children without contraindications to the medications used for HCV should undergo liver biopsy to determine the presence and degree of fibrosis. In the absence of fibrosis, treatment may be deferred. If any degree of hepatic fibrosis is present, antiviral therapy for HCV should be considered. At present, in the United States, the only therapy approved for children by the Food and Drug Administration (FDA) is a combination of interferon (IFN) alfa-2b and ribavirin. No safe therapies have been established for children younger than 3 years of age. Pegylated interferon in combination with ribavirin may be considered in adolescents older than 16 years of age who are post-pubertal, or in younger children in the context of clinical trials. Multicenter trials are currently underway to determine the safety and effectiveness of other forms of therapy for HCV infection in children.

UR - http://www.scopus.com/inward/record.url?scp=7944232728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944232728&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:7944232728

VL - 7

SP - 373

EP - 379

JO - Current Treatment Options in Gastroenterology

JF - Current Treatment Options in Gastroenterology

SN - 1092-8472

IS - 5

ER -